<?xml version="1.0" encoding="UTF-8"?>
<p id="Par60">When a newly authorised medicinal product in a country already has a marketing authorisation in a reference country, the IPVG recommends alignment with the periodicity and submission frequency for the medicinal product in the reference country or alignment with the periodicity and submission frequency as described in the European Union Reference Dates (EURD) list (see the glossary in the Electronic Supplementary Material).</p>
